Understanding how PrEP is made successful: Implementation science needs an evidence-making approach

Pharmacological advances in anti‐retroviral therapy for human immunodeficiency virus‐1 infection: A comprehensive review

“…Additional hydrogen bonds with Glu138 and Ile180 are formed via this linker, as demonstrated by many other NNRTIs. All compounds (20)(21)(22)(23)(24)(25) show superior or equipotent activity of in vitro inhibitory values compared to ETV. 86 RPV and its analogues showed good in vitro inhibition against mutant strains.…”

“…20 Individuals on PrEP will need to take two different ARV medications daily to protect themselves from acquiring HIV from their HIV-positive partner. 21 Un-like TasP and PrEP, PEP is a 28-day course of drugs after an HIV incident within 2 h of exposure and not later than 72 h after exposure. 22 PEP that uses three ARV medications can be given due to occupational or non-occupational exposures with various risks such as sexual, needle sharing, needle stick injuries, sexual assault and other.…”

“…TasP is a treatment to stop HIV from replicating when a person is living with HIV and prevent sexual transmission by reducing the viral load, while PrEP is for HIV‐negative people who possess ongoing risk of HIV 20 . Individuals on PrEP will need to take two different ARV medications daily to protect themselves from acquiring HIV from their HIV‐positive partner 21 . Un‐like TasP and PrEP, PEP is a 28‐day course of drugs after an HIV incident within 2 h of exposure and not later than 72 h after exposure 22 .…”

Editorial: Improving the delivery of pre-exposure prophylaxis (PrEP) to eliminate vertical HIV transmission

“…Many countries in East and Southern Africa with high HIV burden have integrated oral PrEP into HIV prevention programs ( 4 ), in the form of daily oral tenofovir disoproxil fumarate (TDF) containing regimens. While daily oral TDF-based PrEP use in pregnancy and lactation is considered safe and effective ( 5 ), only recently are data on PrEP implementation and extended safety emerging ( 6 – 8 ). As additional PrEP options become available ( 9 ), there is a need for more evidence on how to ensure effective antenatal and postnatal use ( 10 ).…”